The acquisition aims to bolster the pipeline for rare diseases by integrating innovative small interfering RNA (siRNA) assets. Merck KGaA is using the transaction to expand its presence in the science-driven research of orphan diseases.
Tuesday, October 20, 2026
Story
Merck KGaA Buys Silence Therapeutics for $1.1B in Cash
Business1 day ago
Shares of Silence Therapeutics jumped 4.8% in pre-market trading after the company accepted a buyout offer from Merck KGaA. The German science firm will pay $20 per American Depositary Share in an all-cash deal, valuing the company at approximately $1.1 billion.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.